Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts

Holger N. Lode, Przemysław Holko, Aleksandra Wieczorek, Katarzyna Śladowska, Nikolai Siebert, Dominique Valteau-Couanet, Alberto Garaventa, Adela Cañete, John Anderson, Isaac Yaniv, Shifra Ash, Lucas Moreno, Juliet Gray, Roberto Luksch, Genevieve Laureys, Cormac Owens, Carla Manzitti, Sascha Troschke-Meurer, Paweł Kawalec, Ruth L. Ladenstein

Open source

DOI: 10.3390/biomedicines14102200
Published: 2026-09-29
Container: Biomedicines
Publisher: MDPI AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/biomedicines14102200,
  title = {Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts},
  author = {Holger N. Lode and Przemysław Holko and Aleksandra Wieczorek and Katarzyna Śladowska and Nikolai Siebert and Dominique Valteau-Couanet and Alberto Garaventa and Adela Cañete and John Anderson and Isaac Yaniv and Shifra Ash and Lucas Moreno and Juliet Gray and Roberto Luksch and Genevieve Laureys and Cormac Owens and Carla Manzitti and Sascha Troschke-Meurer and Paweł Kawalec and Ruth L. Ladenstein},
  year = {2026},
  journal = {Biomedicines},
  doi = {10.3390/biomedicines14102200},
  url = {https://doi.org/10.3390/biomedicines14102200}
}

RIS

TY  - JOUR
TI  - Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts
AU  - Holger N. Lode
AU  - Przemysław Holko
AU  - Aleksandra Wieczorek
AU  - Katarzyna Śladowska
AU  - Nikolai Siebert
AU  - Dominique Valteau-Couanet
AU  - Alberto Garaventa
AU  - Adela Cañete
AU  - John Anderson
AU  - Isaac Yaniv
AU  - Shifra Ash
AU  - Lucas Moreno
AU  - Juliet Gray
AU  - Roberto Luksch
AU  - Genevieve Laureys
AU  - Cormac Owens
AU  - Carla Manzitti
AU  - Sascha Troschke-Meurer
AU  - Paweł Kawalec
AU  - Ruth L. Ladenstein
PY  - 2026
JO  - Biomedicines
DO  - 10.3390/biomedicines14102200
UR  - https://doi.org/10.3390/biomedicines14102200
ER  -

APA

Lode, H. N., Holko, P., Wieczorek, A., Śladowska, K., Siebert, N., Valteau-Couanet, D., Garaventa, A., Cañete, A., Anderson, J., Yaniv, I., Ash, S., Moreno, L., Gray, J., Luksch, R., Laureys, G., Owens, C., Manzitti, C., Troschke-Meurer, S., Kawalec, P., & Ladenstein, R. L. (2026). Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts. Biomedicines. https://doi.org/10.3390/biomedicines14102200

Source records

crossref · retrieved 2026-11-10T19:02:58.379Z